Research ArticleAccepted Article
Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis
Alicia Rodriguez-Pla, Roscoe L. Warner, David Cuthbertson, Simon Carette, Nader A. Khalidi, Curry L. Koening, Carol A. Langford, Carol A. McAlear, Larry W. Moreland, Christian Pagnoux, Philip Seo, Ulrich Specks, Antoine G. Sreih, Steven R. Ytterberg, Kent J. Johnson, Peter A. Merkel and Paul A. Monach for the Vasculitis Clinical Research Consortium
The Journal of Rheumatology September 2019, jrheum.190093; DOI: https://doi.org/10.3899/jrheum.190093
Alicia Rodriguez-Pla
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Roscoe L. Warner
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
David Cuthbertson
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Simon Carette
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Nader A. Khalidi
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Curry L. Koening
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Carol A. Langford
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Carol A. McAlear
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Larry W. Moreland
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Christian Pagnoux
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Philip Seo
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Ulrich Specks
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Antoine G. Sreih
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Steven R. Ytterberg
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Kent J. Johnson
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Peter A. Merkel
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
Paul A. Monach
From Boston University, Boston, MA, USA; University of Arizona, Tucson, AZ, USA; University of Michigan, Ann Arbor, MI, USA; University of South Florida, Tampa, FL, USA; Mount Sinai Hospital, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; University of Utah, Salt Lake City, UT, USA; Cleveland Clinic, Cleveland, OH, USA; University of Pennsylvania, Philadelphia, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Johns Hopkins University, Baltimore, MD, USA; Mayo Clinic, Rochester, MN, USA; VA Boston Healthcare System, Boston, MA, USA. This work was sponsored by the Vasculitis Clinical Research Consortium. The Vasculitis Clinical Research Consortium (VCRC) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), U54 AR057319), and has received funding from the National Center for Research Resources (U54 RR019497). Additional funding for this project included RC1 AR 058303 and P60 AR047785. Dr. Merkel reports receiving funds for the following activities: Consulting: AbbVie, AstraZeneca, Biogen, Boeringher-Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Insmed, Jannsen, Kiniksa; Research Support: AstraZeneca, Boeringher- Ingelheim, Bristol-Myers Squibb, Celgene, ChemoCentryx, Genentech/Roche, GlaxoSmithKline, Kypha, TerumoBCT; Royalties: UpToDate. Dr. Monach reports receiving funds for the following activities: Consulting: Celgene, ChemoCentryx. Address correspondence to Paul Monach, MD, PhD Rheumatology Section VA Boston Healthcare System 150 South Huntington Ave Boston, MA 02130. Email: Paul.Monach@va.gov, pmonach@bwh.harvard.edu
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis
Alicia Rodriguez-Pla, Roscoe L. Warner, David Cuthbertson, Simon Carette, Nader A. Khalidi, Curry L. Koening, Carol A. Langford, Carol A. McAlear, Larry W. Moreland, Christian Pagnoux, Philip Seo, Ulrich Specks, Antoine G. Sreih, Steven R. Ytterberg, Kent J. Johnson, Peter A. Merkel, Paul A. Monach
The Journal of Rheumatology Sep 2019, jrheum.190093; DOI: 10.3899/jrheum.190093
Accepted manuscript
Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis
Alicia Rodriguez-Pla, Roscoe L. Warner, David Cuthbertson, Simon Carette, Nader A. Khalidi, Curry L. Koening, Carol A. Langford, Carol A. McAlear, Larry W. Moreland, Christian Pagnoux, Philip Seo, Ulrich Specks, Antoine G. Sreih, Steven R. Ytterberg, Kent J. Johnson, Peter A. Merkel, Paul A. Monach
The Journal of Rheumatology Sep 2019, jrheum.190093; DOI: 10.3899/jrheum.190093